1975
DOI: 10.1021/ja00842a058
|View full text |Cite
|
Sign up to set email alerts
|

Asymmetric hydrogenation with a complex of rhodium and a chiral bisphosphine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
154
0
9

Year Published

1998
1998
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 430 publications
(166 citation statements)
references
References 0 publications
3
154
0
9
Order By: Relevance
“…Some prominent examples of chiral bidentate phosphines include Kagan's DIOP [2], Knowles' DIPAMP [3], or Noyori's BINAP [4 -8], all of which became key components of many transition metal catalysts that are now widely used in organic and organometallic chemistry. Chirality is introduced into the structure of these ligands in several ways, viz.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Some prominent examples of chiral bidentate phosphines include Kagan's DIOP [2], Knowles' DIPAMP [3], or Noyori's BINAP [4 -8], all of which became key components of many transition metal catalysts that are now widely used in organic and organometallic chemistry. Chirality is introduced into the structure of these ligands in several ways, viz.…”
Section: Introductionmentioning
confidence: 99%
“…Chirality is introduced into the structure of these ligands in several ways, viz. by inserting a chiral backbone [2, 4 -8], introducing P-centered chirality [3], or attaching readily available chiral ancillary substituents as e. g. in bidentate bis-phosphetanes [9,10] or bis-phospholanes [11 -16], respectively. Although many commonly applied ligands stand out by their C 2 -symmetrical molecular structures, which were long thought to have a beneficial effect on asymmetric induction [17], it has recently been pointed out that C 1 -symmetric ligands may provide similar or even superior enantiocontrol [18].…”
Section: Introductionmentioning
confidence: 99%
“…Its high capacity for asymmetric induction, up to 88%, was demonstrated in the hydrogenation of -dehydroamino acids and enamides [5], and these excellent results stimulated the design and synthesis of many other C2-symmetric phosphine ligands. The most notable ligand reported in the period up to 1979 was 1,2-bis(o-anisylphenylphosphino)ethane (DIPAMP) developed by Knowles (Nobel laureate in 2001) et al at Monsanto in 1975, which provided very high enantioselectivity values up to 96% in the hydrogenation of -dehydroamino acids [6]. The methodology was used to produce (S)-3-(3,4-dihydroxyphenyl)alanine (L-DOPA), which is useful in the treatment of Parkinson's disease.…”
Section: Scheme 2 First Example Of Homogeneous Asymmetric Hydrogenationmentioning
confidence: 99%
“…Knowles liderou o desenvolvimento deste projeto, onde o aminoácido desejado foi obtido com elevados excessos enantioméricos (ee), por meio de uma reação catalítica assimétrica de hidrogenação de um alceno utilizando como ligante uma fosfina quiral, (R,R)-DIPAMP (Esquema 1). 9 Da mesma forma, diversas classes de fármacos puderam ou ainda serão beneficiadas pelos avanços da catálise assimétrica. Dentre as já beneficiadas citam-se: anti-inflamatórios não esteroidais, beta-bloqueadores, agentes anti-hipertensivos, antibióticos, antidepressivos, anticonvulsivantes, antivirais, anti-hipercolesterolemicos, antiparkinsonianos, etc.…”
Section: Introductionunclassified